Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

Clinics in Dermatology

Volumn 31, Issue 4, 2013, Pages 432-437

  Fett, Nicole ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMIQUIMOD; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PLACEBO; PSORALEN; SILDENAFIL; STEROID; TACROLIMUS;

ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; COMORBIDITY; DRUG DOSE REDUCTION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MORBIDITY; MORPHEA; MORTALITY; NOMENCLATURE; OUTCOME ASSESSMENT; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; RETROPERITONEAL FIBROSIS; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTOTHERAPY; PROGNOSIS; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 84879567198     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.01.010     Document Type: Article

References (90)

1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011, 6:509-537.
3. Zulian F., Athreya B.H., Laxer R., et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford) 2006, 45:614-620.
4. Christen-Zaech S., Hakim M.D., Afsar F.S., Paller A.S. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008, 59:385-396.
5. Leitenberger J.J., Cayce R.L., Haley R.W., Adams-Huet B., Bergstresser P.R., Jacobe H.T. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009, 145:545-550.
6. Marzano A.V., Menni S., Parodi A., et al. Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003, 13:171-176.
7. Lawrence R.C., Helmick C.G., Arnett F.C., et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
8. Romano E., Manetti M., Guiducci S., Ceccarelli C., Allanore Y., Matucci-Cerinic M. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol 2011, 29(Suppl 65):S75-S86.
9. Fett N., Werth V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011, 64:217-228. quiz 29-30.
10. Bleasel N.R., Stapleton K.M., Commens C., Ahern V.A. Radiation-induced localized scleroderma in breast cancer patients. Australas J Dermatol 1999, 40:99-102.
11. Davis D.A., Cohen P.R., McNeese M.D., Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996, 35:923-927.
12. Yamamoto T. Chemokines and chemokine receptors in scleroderma. Int Arch Allergy Immunol 2006, 140:345-356.
13. Gambichler T., Skrygan M., Labanski A.A., Kolios A.G., Altmeyer P., Kreuter A. Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma. Regul Pept 2011, 170:4-6.
14. Kurzinski K., Torok K.S. Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine 2011, 55:157-164.
15. Badea I., Taylor M., Rosenberg A., Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009, 48:213-221.
16. Asano Y., Ihn H., Jinnin M., Mimura Y., Tamaki K. Involvement of alphavbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006, 126:1761-1769.
17. Higley H., Persichitte K., Chu S., Waegell W., Vancheeswaran R., Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994, 37:278-288.
18. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995, 287:193-197.
19. Brown M., Postlethwaite A.E., Myers L.K., Hasty K.A. Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts. Clin Rheumatol 2012, 25.
20. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
21. Walker J.G., Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007, 19:580-591.
22. Walker U.A., Tyndall A., Czirjak L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007, 66:754-763.
23. Arkachaisri T., Fertig N., Pino S., Medsger T.A. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 2008, 35:2439-2444.
24. Takehara K., Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005, 44:274-279.
25. Guevara-Gutierrez E., Yinh-Lao J., Garcia-Gutierrez P., Tlacuilo-Parra A. Frequency of antinuclear antibodies in mestizo Mexican children with morphea. Clin Rheumatol 2010, 29:1055-1059.
26. Milano A., Pendergrass S.A., Sargent J.L., et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008, 3:e2696.
27. Curtis A.C., Jansen T.G. The prognosis of localized scleroderma. AMA Arch Derm 1958, 78:749-755. discussion 55-7.
28. Birdi N., Laxer R.M., Thorner P., Fritzler M.J., Silverman E.D. Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum 1993, 36:410-415.
29. Christianson H.B., Dorsey C.S., Kierland R.R., O'Leary P.A. Localized scleroderma; a clinical study of two hundred thirty-five cases. AMA Arch Derm 1956, 74:629-639.
30. Falanga V., Medsger T.A., Reichlin M., Rodnan G.P. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986, 104:849-857.
31. Zulian F., Vallongo C., Woo P., et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005, 52:2873-2881.
32. Kister I., Inglese M., Laxer R.M., Herbert J. Neurologic manifestations of localized scleroderma: a case report and literature review. Neurology 2008, 71:1538-1545.
33. Zannin M.E., Martini G., Athreya B.H., et al. Ocular involvement in children with localised scleroderma: a multi-centre study. Br J Ophthalmol 2007, 91:1311-1314.
34. Kroft E.B., de Jong E.M., Evers A.W. Psychological distress in patients with morphea and eosinophilic fasciitis. Arch Dermatol 2009, 145:1017-1022.
35. Orzechowski N.M., Davis D.M., Mason T.G., Crowson C.S., Reed A.M. Health-related quality of life in children and adolescents with juvenile localized scleroderma. Rheumatology (Oxford) 2009, 48:670-672.
36. es M.D., Lacey J.V., Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003, 48:2246-2255.
37. Elhai M., Meune C., Avouac J., Kahan A., Allanore Y. Trends in mortality 451 in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012, 51(6):1017-1026.
38. Ioannidis J.P., Vlachoyiannopoulos P.G., Haidich A.B., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118:2-10.
39. Kawut S.M., Taichman D.B., Archer-Chicko C.L., Palevsky H.I., Kimmel S.E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003, 123:344-350.
40. Karassa F.B., Ioannidis J.P. Mortality in systemic sclerosis. Clin Exp Rheumatol 2008, 26(Suppl 51):S85-S93.
41. Kowal-Bielecka O., Avouac J., Pittrow D., et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. Chest 2010, 37:105-115.
42. Nihtyanova S.I., Tang E.C., Coghlan J.G., Wells A.U., Black C.M., Denton C.P. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010, 103:109-115.
43. Latsi P.I., Wells A.U. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003, 15:748-755.
44. Wigley F.M., Lima J.A., Mayes M., McLain D., Chapin J.L., Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005, 52:2125-2132.
45. Walker K.M., Pope J. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011, 38:1326-1328.
46. Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008 F;34:161-79; viii.
47. Quillinan N.P., Denton C.P. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009, 21:636-641.
48. Opitz C., Klein-Weigel P.F., Riemekasten G. Systemic sclerosis-a systematic overview: part 2-immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011, 40:20-30.
49. Fett N., Werth V.P. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011, 64:231-242. quiz 43-4.
50. Zwischenberger B.A., Jacobe H.T. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol 2011, 65:925-941.
51. Li S.C., Torok K.S., Pope E., Dedeoglu F., et al. Development of consensus treatment plans for juvenile localized scleroderma. Arthritis Care and Res 2012, 64(8):1175-1185.
52. Kroft E.B., Groeneveld T.J., Seyger M.M., de Jong E.M. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009, 10:181-187.
53. Dytoc M., Ting P.T., Man J., Sawyer D., Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005, 153:815-820.
54. Pope E., Doria A.S., Theriault M., Mohanta A., Laxer R.M. Topical imiquimod 5% cream for pediatric plaque morphea: a prospective, multiple-baseline, open-label pilot study. Dermatology 2011, 223:363-369.
55. Dytoc M.T., Kossintseva I., Ting P.T. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol 2007, 157:615-618.
56. Cunningham B.B., Landells I.D., Langman C., Sailer D.E., Paller A.S. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998, 39(2 Pt 1):211-215.
57. Kreuter A., Hyun J., Stucker M., Sommer A., Altmeyer P., Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006, 54:440-447.
58. Kerscher M., Dirschka T., Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995, 28:346-1166.
59. Kerscher M., Meurer M., Sander C., et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol 1996, 132:1280-1282.
60. Kerscher M., Volkenandt M., Gruss C., et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998, 38:21-26.
61. Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Rocken M. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 1994;14;343:1233.
62. Andres C., Kollmar A., Mempel M., Hein R., Ring J., Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2009, 8.
63. Stege H., Berneburg M., Humke S., et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997, 36(6 Pt 1):938-944.
64. de Rie M.A., Enomoto D.N., de Vries H.J., Bos J.D. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003, 207:298-301.
65. Morita A., Kobayashi K., Isomura I., Tsuji T., Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000, 43:670-674.
66. Kroft E.B., van de Kerkhof P.C., Gerritsen M.J., de Jong E.M. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol 2008, 22:839-844.
67. Gruss C.J., Von Kobyletzki G., Behrens-Williams S.C., et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001, 17:149-155.
68. Jacobe H.T., Cayce R., Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol 2008, 159:691-696.
69. El-Mofty M., Mostafa W., El-Darouty M., et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol Photoimmunol Photomed 2004, 20:148-156.
70. Sator P.G., Radakovic S., Schulmeister K., Honigsmann H., Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol 2009, 60:786-791.
71. Uziel Y., Feldman B.M., Krafchik B.R., Yeung R.S., Laxer R.M. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000, 136:91-95.
72. Zulian F., Martini G., Vallongo C., et al. Methotrexate in juvenile localized scleroderma: a randomised, double-blind, placebo-controlled trial. Arthritis and Rheum 2011, 63(7):1998-2006.
73. Kreuter A., Gambichler T., Breuckmann F., et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005, 141:847-852.
74. Torok K.S., Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 2012, 39:286-294.
75. Seyger M.M., van den Hoogen F.H., de Boo T., de Jong E.M. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998, 39(2 Pt 1):220-225.
76. Martini G., Ramanan A.V., Falcini F., Girschick H., Goldsmith D.P., Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology (Oxford) 2009, 48:1410-1413.
77. Strauss R.M., Bhushan M., Goodfield M.J. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol 2004, 150:790-792.
78. Crespo M.P., Mas I.B., Diaz J.M., Costa A.L., Nortes I.B. Rapid response to cyclosporine and maintenance with methotrexate in linear scleroderma in a young girl. Pediatr Dermatol 2009, 26:118-120.
79. Neustadter J.H., Samarin F., Carlson K.R., Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 2009, 145:127-130.
80. Kaur S., Dhar S., Kanwar A.J. Treatment of childhood linear morphea with D-penicillamine. Pediatr Dermatol 1993, 10:201-202.
81. van Bergen B.H., van Dooren-Greebe R.J., Fiselier T.J., Koopman R.J. D-penicillamine in treatment of scleroderma "en coup de sabre". Hautarzt 1997, 48:42-44.
82. Moinzadeh P., Krieg T., Hunzelmann N. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010, 63:e102-e104.
83. Diab M., Coloe J.R., Magro C., Bechtel M.A. Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 2010, 146:601-604.
84. Roos N., Poulalhon N., Farge D., Madelaine I., Mauviel A., Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007, 321:583-589.
85. Shimizu H, Takahashi M, Takeda S, et al. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 2004;15;77:1661-7.
86. Gao R., Lu Y., Xin Y.P., Zhang X.H., Wang J., Li Y.P. The effects of different immunosuppressants on chronic allograft nephropathy by affecting the transforming growth factor-beta and Smads signal pathways. Transplant Proc 2006, 38:2154-2157.
87. Derk C.T., Grace E., Shenin M., Naik M., Schulz S., Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009, 48:1595-1599.
88. Petrova DT, Brehmer F, Schultze FC, et al. Differential kidney proteome profiling in a murine model of renal fibrosis under treatment with mycophenolate mofetil. Pathobiology 2011;26;78:162-70.
89. Manzia T.M., Angelico R., Toti L., et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl Int 2011, 24:461-468.
90. Scheel PJ Jr., Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med. 2011;4;154:31-6.